Adult Chronic Immune Thrombocytopenia
Target: Spleen tyrosine kinase (SYK)
| Pre-Clinical | Phase 1 | Phase 2 | REGISTRATIONAL | Approved |
|---|---|---|---|---|
|
Pre-Clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
REGISTRATIONAL
Complete
|
Approved
Complete
|
R/R mIDH1 Acute Myeloid Leukemia
Target: Mutant isocitrate dehydrogenase–1 (mIDH1)
| Pre-clinical | Phase 1 | Phase 2 | REGISTRATIONAL | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
REGISTRATIONAL
Complete
|
Approved
Complete
|
RET+ Non-Small Cell Lung Cancer & Advanced Thyroid Cancer
Target: Rearranged During Transfection (RET)
| Pre-clinical | Phase 1 | Phase 2 | REGISTRATIONAL | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
Complete
|
REGISTRATIONAL
Complete
|
Approved
Complete
|
Rheumatoid Arthritis
Target: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)
| Pre-clinical | Phase 1 | Phase 2 | REGISTRATIONAL | Approved |
|---|---|---|---|---|
|
Pre-clinical
Complete
|
Phase 1
Complete
|
Phase 2
In Progress
|
REGISTRATIONAL
Not Started
|
Approved
Not Started
|
CNS Diseases
Target: RIPK1
| Pre-clinical | Phase 1 | Phase 2 | REGISTRATIONAL | Approved |
|---|---|---|---|---|
|
Pre-clinical
In Progress
|
Phase 1
Not Started
|
Phase 2
Not Started
|
REGISTRATIONAL
Not Started
|
Approved
Not Started
|
1 Please see the TAVALISSE Full Prescribing Information
2 Please see the REZLIDHIA Full Prescribing Information, including Boxed WARNING
3 Please see the GAVRETO Full Prescribing Information
4 Rigel also has partnerships with BerGenBio (bemcentinib) and Daiichi Sankyo (milademetan)
* Investigational compound - has not been submitted for approval by FDA